Key inclusion criteria
• Documented histological or cytological
diagnosis of RCC with a clear cell component
• Karnofsky Performance Score (KPS) ≥ 70%
• Measurable disease per RECIST 1.1
1-2 lines of prior therapy for advanced
or
Randomization
Placebo +
cabozantinib
CB-839 +
cabozantinib
Primary endpoint
Progression-free survival
Key exclusion criteria
• Prior treatment with cabozantinib (or other
Met inhibitor) or CB-839
• Untreated or active brain metastases or central
nervous system cancer, as defined
per protocol
• Prior gastric surgery, small bowel resection, or
other conditions that may impede adequate
•
randomization
• Uncontrolled hypertension
CB-839 is an investigational product and is not approved in the United States or any other country.
www.calithera.com
CANTATA
NOW ENROLLING
CB-839 in RCC
For more details about CB-839
clinical trials or to refer patients:
Call: 1-650-870-1028
Visit: www.calithera.com/clinical-trials
Email: clinicaltrials@calithera.com
Calithera Biosciences—Our onco-metabolism
approach brings an enhanced perspective to cancer.
© 201 Calithera. All Rights Reserved.
NCT03428217
/www.calithera.com
/clinical-trials
link